New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
06:10 EDTAZN, DTVStocks with implied volatility below IV index mean; AZN DTV
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 25, DirecTV (DTV) 14.
News For AZN;DTV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
10:58 EDTAZNDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTAZNPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
11:51 EDTAZNExpress Scripts' Medco to pay $7.9M to resolve kickback allegations
Medco Health Solutions, a wholly-owned subsidiary of the pharmacy benefit manager Express Scripts Holding Company (ESRX), of Missouri, has agreed to pay the government $7.9M to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced. Medco provides pharmacy benefit management services to clients who receive subsidies under the Medicare Retiree Drug Subsidy program. The settlement resolves allegations that Medco solicited remuneration from AstraZeneca, a pharmaceutical manufacturer, in exchange for identifying Nexium as the “sole and exclusive” proton pump inhibitor on certain of Medco’s prescription drug lists known as formularies. The United States alleged that Medco received some or all of the remuneration from AstraZeneca in the form of reduced prices on the following AstraZeneca drugs: Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between Medco and AstraZeneca (AZN) violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program. In January 2015, the United States and AstraZeneca reached a $7.9M settlement to resolve kickback allegations arising out of the same conduct. This civil settlement resolves a lawsuit filed under the qui tam, or whistleblower, provision of the False Claims Act, which allows private citizens with knowledge of false claims to bring civil actions on behalf of the government and to share in any recovery. The lawsuit was filed by former AstraZeneca employees Paul DiMattia and F. Folger Tuggle, whose share of the settlement has not been determined. The settlement with Medco was the result of a coordinated effort among the Civil Division, the U.S. Attorney’s Office of the District of Delaware and HHS-OIG.
May 19, 2015
15:05 EDTAZNArdelyx scheduled for end Phase 2 meeting with FDA scheduled in June
Subscribe for More Information
May 18, 2015
08:59 EDTDTVAT&T CEO says gets profitable TV product from 'day one' by buying DirecTV
AT&T (T) CEO Randall Stephenson said AT&T's existing U-verse product is "nice" but unprofitable and that the company will get a profitable TV product from "day one" by buying DireTV (DTV). Stephenson said he expects to take share from cable operators and other TV offerings with its combined offering after the DirecTV deal closes. Stephenson said the company is on target to get the DirecTV deal closed in Q2. Stephenson spoke on CNBC.
08:45 EDTDTVCogent CEO says considering lawsuit against AT&T, CTFinancialNews reports
Subscribe for More Information
06:13 EDTAZNAstraZeneca to invest $285M in new biologics manufacturing facility in Sweden
AstraZeneca announced that it plans to invest approximately $285M in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. It is anticipated that the new facility will supply medicines for clinical trial programs of AstraZeneca and MedImmune, the company’s global biologics research and development arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019. Södertälje is currently home to AstraZeneca’s largest global tablets and capsules manufacturing facility and is also a launch platform site for the company, with specialist capabilities on-site that allow large-scale production of new medicines, working closely with the research and development organisation. By locating the new manufacturing plant in Södertälje, the company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit. The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019. The new manufacturing facility in Sweden will support the progression of drug candidates across the main therapy areas and be aligned with investments being made in the current biologics manufacturing centers, such as the expansion in Frederick, Maryland, announced in November.
May 17, 2015
15:49 EDTAZNAstraZeneca reports Movantik shows 'similar' adverse event rate vs. placebo
Subscribe for More Information
May 15, 2015
09:31 EDTAZNAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
10:37 EDTDTVDISH CEO says AT&T, DirecTV merger will bring tougher competitor
Subscribe for More Information
09:22 EDTAZNLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:37 EDTDTVDISH, Cogent ask FCC to set conditions for AT&T acquisition, Reuters says
DISH (DISH) and Cogent Communications (CCOI) asked the FCC to force AT&T (T) to sell Internet service as a standalone service, as a condition of the telecom giant's proposed acquisition of DirecTV (DTV), according to Reuters. DISH and Cogent also asked the agency to make AT&T sell standalone Internet service at a reasonable price and at the same speeds it provides in package deals, the news service stated. Reference Link
05:52 EDTAZNMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
17:24 EDTAZNAstraZeneca to update progress with immuno-oncology pipeline at ASCO
AstraZeneca and MedImmune, the company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology, or ASCO, Annual Meeting, May 29-June 2. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
May 12, 2015
12:59 EDTDTVRegulators unlikely to block AT&T-DirecTV deal, WSJ says
The FCC and U.S. Justice Department are nearly finished reviewing AT&T's (T) acquisition of DirecTV (DTV), and are unlikely to block the deal, reports The Wall Street Journal, citing people familiar with the matter. Sources said the Justice Department hasn't raised issues, and though the FCC may seek to impose conditions, they are expected to be acceptable to AT&T. Reference Link
12:32 EDTDTVDirecTV up 1% after report says regulators unlikely to block AT&T deal
Dow Jones, citing sources, said the U.S. review of the deal is nearing its end and that regulators are unlikely to step in to block the merger.
12:30 EDTDTVU.S. unlikely to block AT&T, DirecTV deal, Dow Jones reports
Subscribe for More Information
11:14 EDTDTVAOL premium low but likely best bet for AOL shareholders, Bloomberg says
Subscribe for More Information
08:31 EDTDTVApple likely to launch TV video service this year, says Pacific Crest
Subscribe for More Information
May 10, 2015
18:05 EDTDTVFCC contract ruling may speed review of AT&T-DirecTV merger, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use